Oryzon Genomics — Progression across the pipeline in Q3
Oryzon Genomics has reported its Q325 results, a period characterised by tangible progress across its ongoing clinical programmes. Anticipation...
115 Views
Oryzon Genomics — Progress for iadademstat across the board
Oryzon has announced encouraging updates for iadademstat. In acute myeloid leukaemia (AML), positive data was reported for two programmes,...
119 Views
Oryzon Genomics — Making headway towards Phase III in BPD
Oryzon Genomics has announced that it has received FDA feedback on its plans for the Phase III programme in borderline personality disorder (BPD)...
169 Views
Oryzon Genomics — Foray into sickle cell disease
Oryzon Genomics has announced that the European Medicines Agency (EMA) has provided regulatory clearance for a Phase Ib trial of iadademstat in...
206 Views
Oryzon Genomics — Making headway rolling into H225
Oryzon Genomics has reported its Q225 results, summarising an active period. Its programme focused on vafidemstat in borderline personality...
173 Views